FSR Wealth Management Ltd. Invests $238,000 in Axon Enterprise, Inc. (NASDAQ:AXON)

FSR Wealth Management Ltd. purchased a new stake in shares of Axon Enterprise, Inc. (NASDAQ:AXON) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 400 shares of the biotechnology company’s stock, valued at approximately $238,000.

A number of other large investors have also modified their holdings of the company. Asset Dedication LLC lifted its holdings in Axon Enterprise by 11.3% during the 4th quarter. Asset Dedication LLC now owns 178 shares of the biotechnology company’s stock valued at $106,000 after purchasing an additional 18 shares during the last quarter. Bleakley Financial Group LLC grew its position in shares of Axon Enterprise by 1.3% during the 4th quarter. Bleakley Financial Group LLC now owns 1,527 shares of the biotechnology company’s stock worth $908,000 after buying an additional 20 shares during the period. Insigneo Advisory Services LLC boosted its stake in Axon Enterprise by 1.4% in the third quarter. Insigneo Advisory Services LLC now owns 1,568 shares of the biotechnology company’s stock valued at $627,000 after acquiring an additional 22 shares during the last quarter. Menard Financial Group LLC grew its holdings in Axon Enterprise by 0.8% during the 3rd quarter. Menard Financial Group LLC now owns 3,014 shares of the biotechnology company’s stock worth $1,204,000 after acquiring an additional 24 shares during the period. Finally, PFG Investments LLC raised its position in shares of Axon Enterprise by 0.6% during the 3rd quarter. PFG Investments LLC now owns 3,872 shares of the biotechnology company’s stock valued at $1,547,000 after acquiring an additional 25 shares during the last quarter. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages recently commented on AXON. Needham & Company LLC lifted their price objective on Axon Enterprise from $525.00 to $600.00 and gave the stock a “buy” rating in a research note on Friday, November 8th. Robert W. Baird upped their price target on Axon Enterprise from $600.00 to $800.00 and gave the company an “outperform” rating in a research note on Friday, December 6th. JMP Securities lifted their price objective on shares of Axon Enterprise from $610.00 to $725.00 and gave the stock a “market outperform” rating in a research note on Tuesday, February 4th. The Goldman Sachs Group upped their target price on shares of Axon Enterprise from $500.00 to $700.00 and gave the company a “buy” rating in a research note on Monday, January 27th. Finally, Morgan Stanley raised shares of Axon Enterprise from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $500.00 to $700.00 in a research report on Tuesday, December 3rd. One equities research analyst has rated the stock with a hold rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $542.15.

Axon Enterprise Price Performance

NASDAQ:AXON opened at $679.24 on Monday. The company has a quick ratio of 2.63, a current ratio of 2.96 and a debt-to-equity ratio of 0.32. Axon Enterprise, Inc. has a 12-month low of $255.68 and a 12-month high of $698.67. The stock’s 50 day moving average price is $623.43 and its two-hundred day moving average price is $496.32. The firm has a market capitalization of $51.79 billion, a price-to-earnings ratio of 175.51, a P/E/G ratio of 6.79 and a beta of 1.05.

Insider Activity

In related news, Director Julie A. Cullivan sold 1,261 shares of the firm’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $682.06, for a total transaction of $860,077.66. Following the transaction, the director now directly owns 2,392 shares of the company’s stock, valued at approximately $1,631,487.52. This trade represents a 34.52 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, President Joshua Isner sold 20,000 shares of Axon Enterprise stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $606.15, for a total transaction of $12,123,000.00. Following the completion of the sale, the president now owns 208,166 shares of the company’s stock, valued at $126,179,820.90. This trade represents a 8.77 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 50,545 shares of company stock valued at $30,721,337. 6.10% of the stock is owned by insiders.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.